The DOI matches its Crossref record; 382 of the 382 references it cites were found in a registry or an index.
Immunotherapy of Diffuse Gliomas: Biological Background, Current Status and Future Developments
Open accessAbstract
Despite aggressive multimodal treatment approaches, the prognosis for patients with diffuse gliomas remains disappointing. Glioma cells often extensively infiltrate in the surrounding brain parenchyma, a phenomenon that helps them to escape surgical removal, radiation exposure and chemotherapy. Moreover, conventional therapy is often associated with considerable local and systemic side effects. Therefore, the development of novel therapeutic approaches is essential to improve the outcome of these patients. Immunotherapy offers the opportunity to specifically target residual radio—and chemoresistant tumor cells without damaging healthy neighboring brain tissue. Significant progress has been made in recent years both in understanding the mechanisms of immune regulation in the central nervous system (CNS) as well as tumor‐induced and host‐mediated immunosuppression elicited by gliomas. In this review, after discussing the special requirements needed for the initiation and control of immune responses in the CNS, we focus on immunological phenomena observed in glioma patients, discuss different immunological approaches to attack glioma‐associated target structures and touch on further strategies to improve the efficacy of immunotherapy of gliomas.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
The 2007 WHO Classification of Tumours of the Central Nervous System
Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K., Burger, P. C., Jouvet, A., Scheithauer, B. W., & Kleihues, P. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0243-4 · Cited by 15,397
Janeway, C. A., & Medzhitov, R. (2002) · Annual Review of Immunology · doi:10.1146/annurev.immunol.20.083001.084359 · Cited by 8,394
Foxp3 programs the development and function of CD4+CD25+ regulatory T cells
Fontenot, J. D., Gavin, M. A., & Rudensky, A. Y. (2003) · Nature Immunology · doi:10.1038/ni904 · Cited by 7,745
Stupp, R., Hegi, M. E., Mason, W. P., van den Bent, M. J., Taphoorn, M. J., Janzer, R. C., Ludwin, S. K., Allgeier, A., Fisher, B., Belanger, K., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70025-7 · Cited by 7,668
Self-citationMGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405
Bettelli, E., Carrier, Y., Gao, W., Korn, T., Strom, T. B., Oukka, M., Weiner, H. L., & Kuchroo, V. K. (2006) · Nature · doi:10.1038/nature04753 · Cited by 6,992
Immunobiology of Dendritic Cells
Banchereau, J., Briere, F., Caux, C., Davoust, J., Lebecque, S., Liu, Y.-J., Pulendran, B., & Palucka, K. (2000) · Annual Review of Immunology · doi:10.1146/annurev.immunol.18.1.767 · Cited by 6,634
Takeda, K., Kaisho, T., & Akira, S. (2003) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141126 · Cited by 6,143
Chen, W., Jin, W., Hardegen, N., Lei, K.-J., Li, L., Marinos, N., McGrady, G., & Wahl, S. M. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030152 · Cited by 4,699
Research works printed but not linked: 28
- 10.1111/j.1365-2990.1997.tb01315.x · doi:10.1111/j.1365-2990.1997.tb01315.x · Paper page
- 10.1007/BF02893856 · doi:10.1007/bf02893856
- Blancher A, 1993, Local immunotherapy of recurrent glioblastoma multiforme by intracerebral perfusion of interleukin‐2 and LAK cells, Eur Cytokine Netw, 4, 331
- Buccoliero AM, 2006, Inducible cyclooxygenase (COX‐2) in glioblastoma–clinical and immunohistochemical (COX‐2‐VEGF) correlations, Clin Neuropathol, 25, 59
- Castelli MG, 1989, Prostaglandin and thromboxane synthesis by human intracranial tumors, Cancer Res, 49, 1505
- Dunn GP, 2007, Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human glioma, Cancer Immun, 7, 12
- 10.1007/s11060-007-9442-z · doi:10.1007/s11060-007-9442-z
- 10.1016/0008-8749(92)90096-8 · doi:10.1016/0008-8749(92)90096-8
- 10.1002/1521-4141(200211)32:11<3235::AID-IMMU3235>3.0.CO;2-J · doi:10.1002/1521-4141(200211)32:11<3235::aid-immu3235>3.0.co;2-j
- 10.1002/(SICI)1097-0215(19991210)83:6<760::AID-IJC11>3.0.CO;2-R · doi:10.1002/(sici)1097-0215(19991210)83:6<760::aid-ijc11>3.0.co;2-r
- 10.1080/01616412.1990.11739955 · doi:10.1080/01616412.1990.11739955
- Insug O, 2002, A dendritic cell vaccine induces protective immunity to intracranial growth of glioma, Anticancer Res, 22, 613
- Jacobs SK, 1986, Interleukin‐2 or autologous lymphokine‐activated killer cell treatment of malignant glioma: phase I trial, Cancer Res, 46, 2101
- 10.1002/cncr.11122 · doi:10.1002/cncr.11122
- Kim JA, 2001, Divergent effects of 4‐1BB antibodies on antitumor immunity and on tumor‐reactive T‐cell generation, Cancer Res, 61, 2031
- 10.1007/BF00195603 · doi:10.1007/bf00195603
- 10.1517/14712598.4.7.1115 · doi:10.1517/14712598.4.7.1115
- 10.1007/s002620050405 · doi:10.1007/s002620050405
- 10.2739/kurumemedj.44.43 · doi:10.2739/kurumemedj.44.43
- 10.1034/j.1399-0039.2002.600406.x · doi:10.1034/j.1399-0039.2002.600406.x
- 10.1007/BF00205425 · doi:10.1007/bf00205425
- 10.1007/BF02700016 · doi:10.1007/bf02700016
- 10.1093/intimm/11.8.1337 · doi:10.1093/intimm/11.8.1337
- 10.1007/s00262-002-0270-x · doi:10.1007/s00262-002-0270-x
- 10.1007/s00262-008-0461-1 · doi:10.1007/s00262-008-0461-1
- Safdari H, 1979, Histological correlations with survival in malignant gliomas, Acta Neurochir Suppl (Wien), 28, 485
- 10.1158/0008-5472.CAN-05-2967 · doi:10.1158/0008-5472.can-05-2967
- 10.1023/A:1006456421177 · doi:10.1023/a:1006456421177
Cited by
Cisplatin in cancer therapy: Molecular mechanisms of action
Dasari, S., & Bernard Tchounwou, P. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.07.025 · Cited by 5,537
Inflammation and tumor progression: signaling pathways and targeted intervention
Zhao, H., Wu, L., Yan, G., Chen, Y., Zhou, M., Wu, Y., & Li, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00658-5 · Cited by 2,792
The Microenvironmental Landscape of Brain Tumors
Quail, D. F., & Joyce, J. A. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.02.009 · Cited by 1,862
The Pathobiology of Vascular Dementia
Iadecola, C. (2013) · Neuron · doi:10.1016/j.neuron.2013.10.008 · Cited by 1,857
Cancer stem cells in glioblastoma
Lathia, J. D., Mack, S. C., Mulkearns-Hubert, E. E., Valentim, C. L. L., & Rich, J. N. (2015) · Genes & Development · doi:10.1101/gad.261982.115 · Cited by 1,520
Metadata
- Authors
- Grauer, O. M., Wesseling, P., & Adema, G. J.
- Venue
- Brain Pathology
- Publisher
- Wiley
- Published
- 2009-09-04
- Volume
- 19
- Issue
- 4
- Pages
- 674-693
- ISSN
- 1015-6305 (ISSN-L)
- 1750-3639
- OpenAlex
- W2165871546
- Cited by
- 4,007
- References
- 382
- FWCI
- 23.29
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Immunotherapy of Diffuse Gliomas: Biological Background, Current Status and Future Developments. https://app.cochat.ai/papers/10.1111/j.1750-3639.2009.00315.x
- The paper
- Grauer, O. M., Wesseling, P., & Adema, G. J. (2009). Immunotherapy of Diffuse Gliomas: Biological Background, Current Status and Future Developments. Brain Pathology. https://doi.org/10.1111/j.1750-3639.2009.00315.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.